First Trust Nasdaq Pharmaceuticals ETF
FTXH
25 hedge funds and large institutions have $12.9M invested in First Trust Nasdaq Pharmaceuticals ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 8 closing their positions.
8.41% less ownership
Funds ownership: 55.38% → 46.98% (-8.4%)
19% less funds holding
Funds holding: 31 → 25 (-6)
29% less capital invested
Capital invested by funds: $18.1M → $12.9M (-$5.16M)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$573K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$385K |
| 3 |
Goldman Sachs
New York
|
+$218K |
| 4 |
PPWM
Paragon Private Wealth Management
Lexington,
Kentucky
|
+$119K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$66.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPIA
Steward Partners Investment Advisory
New York
|
-$1.78M |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
-$1.2M |
| 3 |
NP
Nilsine Partners
Greenwood Village,
Colorado
|
-$1.13M |
| 4 |
GSIAS
Garden State Investment Advisory Services
Red Bank,
New Jersey
|
-$565K |
| 5 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$352K |
FTXH Hedge Fund Activity: Q2 2023 in Review
25 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2023, worth a combined $12.9M — down 29% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of FTXH and 2 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Old Mission Capital, opening a new position worth an estimated $573K. The largest seller was Steward Partners Investment Advisory, cutting an estimated $1.78M.
- 25 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2023, down from 31 in Q1 2023.
- Funds reported $12.9M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2023, down 29% quarter-over-quarter.
- 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2023 and 8 closed out, a net change of -6 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2023 was Old Mission Capital, an estimated $573K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2023 was Steward Partners Investment Advisory, an estimated $1.78M sold.
Based on aggregated 13F filings for Q2 2023.